Trials / Not Yet Recruiting
Not Yet RecruitingNCT07525635
Aspirin Dosing in Pregnancy
Aspirin Dosing and Platelet Phenotype in Pregnancy
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin | 81mg twice a day (162mg total) |
Timeline
- Start date
- 2026-04-15
- Primary completion
- 2027-08-01
- Completion
- 2028-02-20
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07525635. Inclusion in this directory is not an endorsement.